Assess whether labeling language overclaims the evidence (1799d0)

Situation

After a literature paper the 505(b)(2) package leans on getting retracted, 505(b)(2) literature-to-product bridge table is what 505(b)(2) development lead can touch in a mid-size sponsor after a complete response letter. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Clinical and Evidence Strategy file.

Decision

505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• 505(b)(2) literature-to-product bridge table reads as Proceed under protocol once a literature paper the 505(b)(2) package leans on getting retracted is lined up to the same Pharma & Life Sciences population.
• 505(b)(2) literature-to-product bridge table is closer to Pause the pathway after a literature paper the 505(b)(2) package leans on getting retracted; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract.
• Escalate safety review is still live in 505(b)(2) literature-to-product bridge table for 505(b)(2) development lead in a mid-size sponsor after a complete response letter.
• 505(b)(2) literature-to-product bridge table is missing the fact 505(b)(2) development lead needs after a literature paper the 505(b)(2) package leans on getting retracted; stop this Pharma & Life Sciences close.

Analysis required

• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim 505(b)(2) development lead would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a literature paper the 505(b)(2) package leans on getting retracted.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move labeling language overclaims the for 505(b)(2) development lead.

Recommendation